Bioavailability Production Scientist 
Camargo
FEBRUARY 10, 2021
Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Pharmacokinetics (PK) and bioequivalence (BE) studies serve as the foundation of determining the fate of drug products. Pharmacokinetic Modeling: Non-Linear Mixed Effects Modeling.
Pharmaceutical Technology
FEBRUARY 23, 2023
Quotient Sciences helps biotech and pharma customers in the development and optimization of drug products. Our chemists and formulation scientists review the properties of new drug candidates and “work their magic” to develop formulations that improve the exposure profile of the compound.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Camargo
DECEMBER 22, 2021
One of Camargo’s differentiating offerings is the portfolio analysis, a high-level, integrated evaluation of the scientific, medical, regulatory, and commercial viability of each product within a sponsor’s portfolio. Each product is unique, and so is the associated development strategy. Why Conduct a Portfolio Analysis?
Pharmaceutical Technology
APRIL 20, 2023
It also aims to contribute to the pharmaceutical sector by facilitating cross-industry partnerships and research-based product development. Roquette has appointed a new team of research scientists and formulation experts to offer guidance to the facility and to the company’s global pharmaceutical R&D activities.
Pharmaceutical Technology
AUGUST 3, 2022
The potential to use these scientific breakthroughs to make a real difference to patients’ lives is what drives many highly skilled scientists to the world of drug development. This is an exact science as the generation of too-fine or not-fine-enough powder will have a huge impact on the end-product.
Pharmaceutical Technology
FEBRUARY 13, 2023
Quotient Sciences was asked to select the best candidate based on material science and oral bioavailability considerations. We select the appropriate salt or physical form to optimize a molecule for both manufacturability and downstream product performance.
Cloudbyz
MARCH 5, 2024
The difference between biologics vs small molecules in pharma drug development In pharmaceutical drug development, biologics and small molecules represent two distinct categories of medicinal products, each with their own unique characteristics, development processes, and mechanisms of action.
Expert insights. Personalized for you.
133 
Let's personalize your content